Tratamiento farmacológico antiinflamatorio no esteroide oral para la fibrosis quística
Información
- DOI:
- https://doi.org/10.1002/14651858.CD001505.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 17 octubre 2007see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Fibrosis quística y enfermedades genéticas
- Copyright:
-
- Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Anna Crighton had the original idea for the review, drafted the protocol, extracted data and co‐authored the review. Carol Dezateux drafted the protocol and data extraction forms, extracted and analyzed data and was responsible for writing the review.
Anna Crighton and Carol Dezateux stepped down from the review as from February 2006.
Larry Lands took over as lead reviewer in May 2004. He led on the update of the review and acts as guarantor of the review.
Sanja Stanojevic joined the review in June 2006. She extracted and analyzed data for the subsequent updates and co‐authored the review.
Sources of support
Internal sources
-
Institute of Child Health, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
External sources
-
Tenovus, Scotland, UK.
Declaraciones de interés
Dr Larry Lands fue el investigador principal en el Ensayo transcanadiense (Lands 2007)).
Agradecimientos
Se agradece al profesor Ros Smyth, a Jill Motley, a Nikki Jahnke y al Grupo Cochrane Editorial de Fibrosis Quística y Trastornos Genéticos (Cochrane Cystic Fibrosis and Genetic Disorders Editorial Group) por su apoyo valioso; a la profesora Carol Dezateux y a Anna Crighton por sus aportaciones a las versiones anteriores de esta revisión; al Dr. Michael Konstan por sus observaciones útiles sobre un borrador anterior de la revisión original; y al Dr. Somnath Mukhopadhyay por su estímulo.
Version history
Published | Title | Stage | Authors | Version |
2019 Sep 09 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
2016 Apr 07 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
2013 Jun 13 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
2007 Oct 17 | Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis | Review | Larry C Lands, Sanja Stanojevic | |
1999 Apr 26 | Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis | Review | Larry C Lands, Carol Dezateux, A Crighton, Sanja Stanojevic | |
Differences between protocol and review
There was a post‐hoc subgroup analysis of the lung function data split by age (two groups: 'under 13 years at randomisation' and '13 years and over at randomisation').
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Adolescent; Adult; Child; Child, Preschool; Humans;
PICO
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
1 Annual rate of change in % predicted FEV1 Show forest plot | 2 | 226 | Mean Difference (IV, Fixed, 95% CI) | 1.32 [0.21, 2.42] |
2 Annual rate of change in % predicted FEV1 (split by age) Show forest plot | 2 | 226 | Mean Difference (IV, Fixed, 95% CI) | 1.16 [0.07, 2.25] |
2.1 Under 13 years at randomisation | 2 | 147 | Mean Difference (IV, Fixed, 95% CI) | 1.41 [0.03, 2.80] |
2.2 13 years or over at randomisation | 2 | 79 | Mean Difference (IV, Fixed, 95% CI) | 0.75 [‐1.02, 2.52] |
3 Annual rate of change in % predicted FVC Show forest plot | 2 | 226 | Mean Difference (IV, Fixed, 95% CI) | 1.27 [0.26, 2.28] |
4 Annual rate of change in % predicted FVC (split by age) Show forest plot | 2 | 226 | Mean Difference (IV, Fixed, 95% CI) | 1.09 [0.12, 2.06] |
4.1 Under 13 years at randomisation | 2 | 147 | Mean Difference (IV, Fixed, 95% CI) | 1.32 [0.04, 2.60] |
4.2 13 years and over at randomisation | 2 | 79 | Mean Difference (IV, Fixed, 95% CI) | 0.78 [‐0.71, 2.27] |
5 Annual rate of change in % predicted FEF25‐75% Show forest plot | 2 | 218 | Mean Difference (IV, Fixed, 95% CI) | 1.80 [0.15, 3.45] |
6 Annual rate of change in % predicted FEF25‐75% (split by age) Show forest plot | 2 | 214 | Mean Difference (IV, Fixed, 95% CI) | 1.72 [0.10, 3.34] |
6.1 Under 13 years at randomisation | 2 | 138 | Mean Difference (IV, Fixed, 95% CI) | 2.03 [‐0.09, 4.16] |
6.2 13 years or older at randomisation | 2 | 76 | Mean Difference (IV, Fixed, 95% CI) | 1.28 [‐1.22, 3.79] |
7 Proportion with at least one respiratory hospitalisation Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
8 Proportion with at least one hospital admission Show forest plot | 4 | 286 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.61 [0.37, 1.01] |
9 Number of deaths Show forest plot | 3 | 245 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
10 Annual rate of change in % ideal body weight Show forest plot | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
11 Annual rate of change in % ideal body weight (split by age) Show forest plot | 1 | 84 | Mean Difference (IV, Fixed, 95% CI) | 0.81 [0.08, 1.53] |
11.1 Under 13 years at randomisation | 1 | 49 | Mean Difference (IV, Fixed, 95% CI) | 1.45 [0.33, 2.57] |
11.2 13 years or older at randomisation | 1 | 35 | Mean Difference (IV, Fixed, 95% CI) | 0.34 [‐0.61, 1.29] |
12 Chest X‐ray score Show forest plot | 2 | 226 | Mean Difference (IV, Fixed, 95% CI) | 0.37 [‐0.08, 0.81] |
13 Chest X‐ray score (split by age) Show forest plot | 1 | 84 | Mean Difference (IV, Fixed, 95% CI) | 0.51 [‐0.04, 1.07] |
13.1 Under 13 years at randomisation | 1 | 49 | Mean Difference (IV, Fixed, 95% CI) | 0.45 [‐0.24, 1.14] |
13.2 13 years or older at randomisation | 1 | 35 | Mean Difference (IV, Fixed, 95% CI) | 0.63 [‐0.30, 1.56] |
14 Increase in abdominal pain Show forest plot | 2 | 226 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.54 [0.20, 1.48] |
15 Decrease in abdominal pain Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
16 Proportion with at least one gastrointestinal hospitalisation Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
17 Stool frequency Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
18 Occult blood Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
19 Increase in epistaxis Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
20 Decrease in epistaxis Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
21 Increase in conjunctivitis Show forest plot | 2 | 226 | Peto Odds Ratio (Peto, Fixed, 95% CI) | 0.72 [0.22, 2.40] |
22 Decrease in conjunctivitis Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
23 Increase in nausea Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |
24 Increase in diarrhoea Show forest plot | 1 | Peto Odds Ratio (Peto, Fixed, 95% CI) | Totals not selected | |